Family Office · Parramatta, NSW, Australia
SK Capital Partners is a private investment firm founded in 2007, specializing in the chemicals, materials, and pharmaceuticals sectors. Headquartered in New York City, the firm manages more than $7 billion in assets and focuses on acquiring and building businesses with strong growth potential. SK Capital Partners is known for its operational expertise and has a portfolio that includes several prominent companies in specialty chemicals and pharmaceuticals. The firm has a track record of driving transformation and value creation in its investments, with recent activity including strategic acquisitions and divestitures in its core industries.
Business models
services, biotech_therapeutics
Customer segments
Enterprise, Mid-market
Geography
US, Europe, APAC, LATAM
+ 3 more deals. Score your deck to see the full investment history.
We never publish partner emails directly. Score your deck to unlock contacts for the firms ranked as best-fit.
SK Capital Partners deploys privately-held capital. Cycles are short, decisions concentrated, and structures flexible (equity, convertible, revenue-share). Less brand premium, more underwriting on substance. VC Boom tracks SK Capital Partners alongside 47,000+ other active investors, ranked weekly by recent-deal momentum, sector concentration, and partner activity.
Seed VC
Bic Securities
pharmaceuticals, healthcare, software / ERP
Family Office
Lobnek Wealth Management
life sciences, private equity, M&A
Family Office
Aeternum Management AS
life sciences, healthcare, medical devices
Seed VC
4BIO Capital
advanced therapies, gene therapy, life sciences
Seed VC
East West Capital Partners
pharmaceuticals, biotech, medical technology
Family Office
Wholesale Investor
pharmaceuticals, medical devices, healthtech
Drop your pitch. AI scores it on the 8 dimensions VCs read for and ranks the 47,000+ active investors in the database by fit. SK Capital Partners is one of them — and we'll tell you exactly where they sit in your top 100.